Newgenivf Group LTD F-1 registration statements

NewGenIvf Group Limited filed an F-1 registration statement for the resale of up to 100 million Class A Ordinary Shares by selling securityholders, while detailing its strategic pivot into digital assets, real estate development, and ongoing debt financing.

NewGenIvf Group Limited reported a net income for H1 2025, driven by a bargain purchase gain and capital raises, while expanding into digital assets and UAE real estate.

NewGenIvf Group Limited reports increased revenue but a net loss in 2024, while pursuing strategic investments in digital assets and real estate, and addressing Nasdaq compliance and legal challenges.

NewGenIvf Group Limited reported a net loss in 2024, but secured significant financing and is pursuing new strategic investments in digital assets and real estate while resolving Nasdaq compliance issues.

NewGenIvf Group Limited reported a net loss in 2024 despite revenue growth, while actively securing significant capital and acquiring key technology to fuel its expansion in the Asia-Pacific assisted reproductive services market.

NewGenIvf Group Limited is registering the offer and resale of up to 22,027,500 Class A Ordinary Shares by selling securityholders, aiming to satisfy certain registration rights.

NewGenIvf Group Limited is registering the resale of up to 123,275,000 Class A Ordinary Shares by selling securityholders, following recent business developments and strategic realignments.

NewGenIvf Group Limited is registering for the resale of up to 9,275,000 Class A Ordinary Shares by selling securityholders.

NewGenIvf Group Limited has filed an amendment to its registration statement for the resale of up to 40 million Class A Ordinary Shares by a selling shareholder, White Lion Capital, LLC.

NewGenIvf Group Limited has filed a registration statement for the resale of up to 40 million Class A ordinary shares by a selling shareholder, White Lion Capital, LLC.

NewGenIvf Group Limited is registering up to 139,425,259 Class A Ordinary Shares for resale by selling shareholders following previous private placements of convertible notes and warrants.

NewGenIvf Group Limited has filed an amendment to its registration statement for the resale of up to 139,425,259 Class A Ordinary Shares by selling shareholders.

NewGenIvf Group Limited has filed an amendment to its Form F-1 registration statement, pertaining to the resale of up to 139,425,259 Class A Ordinary Shares by selling shareholders.

Selling shareholders of NewGenIvf Group Limited intend to resell up to 139,425,259 Class A Ordinary Shares, according to a recent filing.

NewGenIvf Group Limited is registering for resale up to 5,912,281 Class A Ordinary Shares by selling shareholders to enhance market liquidity.